for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quidel Corporation

QDEL.OQ

Latest Trade

70.93USD

Change

1.88(+2.72%)

Volume

70,866

Today's Range

69.52

 - 

72.31

52 Week Range

44.31

 - 

72.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
69.05
Open
69.52
Volume
70,866
3M AVG Volume
4.13
Today's High
72.31
Today's Low
69.52
52 Week High
72.31
52 Week Low
44.31
Shares Out (MIL)
41.64
Market Cap (MIL)
2,876.08
Forward P/E
24.88
Dividend (Yield %)
--

Next Event

Q4 2019 Quidel Corp Earnings Release

Latest Developments

More

Quidel Q3 Non-GAAP Earnings Per Share $0.70

Quidel Corp Announces Q2 Revenue Of $108.3 Mln

Quidel Reports Q1 Non-GAAP Earnings Per Share $0.91

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Quidel Corporation

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women's health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Industry

Biotechnology & Drugs

Contact Info

9975 Summers Ridge Road

+1.858.5521100

http://www.quidel.com/

Executive Leadership

Kenneth F. Buechler

Independent Chairman of the Board

Douglas C. Bryant

President, Chief Executive Officer, Director

Randall J. Steward

Chief Financial Officer

Robert Joseph Bujarski

Senior Vice President - Business Development, General Counsel and Corporate Secretary

Michael Donald Abney

Senior Vice President - Distribution

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.3K

2018

0.5K

2019(E)

0.5K
EPS (USD)

2016

-0.420

2017

0.150

2018

3.040

2019(E)

2.750
Price To Earnings (TTM)
39.62
Price To Sales (TTM)
5.58
Price To Book (MRQ)
5.38
Price To Cash Flow (TTM)
23.30
Total Debt To Equity (MRQ)
4.81
LT Debt To Equity (MRQ)
0.84
Return on Investment (TTM)
10.87
Return on Equity (TTM)
9.00

Latest News

Latest News

BRIEF-Quidel Reports Q1 Non-GAAP Earnings Per Share $1.29

* Q1 REVENUE $169.1 MILLION VERSUS I/B/E/S VIEW $150.9 MILLION

BRIEF-Quidel Corp Says Increased Size Of Board To Eight Members - SEC Filing

* QUIDEL CORP SAYS INCREASED SIZE OF COMPANY'S BOARD OF DIRECTORS TO EIGHT MEMBERS - SEC FILING Source text (https://bit.ly/2q4dLBG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Quidel Receives FDA Clearance For Its Instrument

* QUIDEL RECEIVES FDA CLEARANCE FOR ITS POINT-OF-CARE SOFIA® LYME FLUORESCENT IMMUNOASSAY FOR USE WITH SOFIA® 2 INSTRUMENT Source text for Eikon: Further company coverage:

BRIEF-Quidel Q4 Non-Gaap Earnings Per Share $0.56

* QUIDEL REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Quidel Receives 510(K) Clearance For Quickvue Influenza A+B Test

* QUIDEL RECEIVES 510(K) CLEARANCE FOR QUICKVUE INFLUENZA A+B TEST, ASSAY MEETS FDA'S CLASS II RIDT REQUIREMENTS

BRIEF-Quidel Receives FDA Clearance And Clia Waiver For Its Point-Of-Care Sofia® 2 Instrument

* QUIDEL RECEIVES FDA CLEARANCE AND CLIA WAIVER FOR ITS POINT-OF-CARE SOFIA® 2 INSTRUMENT FOR USE WITH SOFIA STREP A+ ASSAY Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

BRIEF-Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

* QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS

BRIEF-Quidel Corp reports Q3 GAAP loss per share $0.16

* Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S

BRIEF-Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

* Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

BRIEF-Quidel gets FDA nod for Solana Assay molecular diagnostic test

* Quidel receives FDA clearance for its Solana RSV + hMPV Assay

BRIEF-Quidel Corp says ‍on Oct 6, co entered into credit agreement​

* Quidel corp says on Oct 6, co entered into credit agreement - sec filing

BRIEF-QUIDEL ANNOUNCES EARLY TERMINATION OF HART-SCOTT-RODINO WAITING PERIOD ON DEAL FOR ALERE'S ASSAY BUSINESS

* QUIDEL ANNOUNCES EARLY TERMINATION OF THE HART-SCOTT-RODINO WAITING PERIOD FOR ITS PENDING ACQUISITION OF ALERE’S TRIAGE® B-TYPE NATURIETIC PEPTIDE (BNP) ASSAY BUSINESS RUN ON BECKMAN COULTER ANALYZERS

BRIEF-Quidel announces revised agreement for pending acquisition of Alere’s business

* Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers

BRIEF-Quidel Q2 GAAP loss per share $0.35

* Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Quidel announces definitive agreement to acquire Alere Triage assets

* Quidel Corp - accretive transactions extend Quidel's market leadership and position it for future growth

BRIEF-Quidel receives FDA clearance and CLIA waiver

* Quidel receives FDA clearance and CLIA waiver for its point-of-care sofia 2 instrument for use with sofia respiratory syncytial virus (RSV) assay Source text for Eikon: Further company coverage:

BRIEF-Quidel receives the CE mark for its thyretain tbi reporter bioassay

* Quidel receives the CE mark for its thyretain® tbi reporter bioassay Source text for Eikon: Further company coverage:

BRIEF-Quidel gets FDA clearance, CLIA waiver for Sofia 2 Immunoassay analyzer

* Quidel receives FDA clearance and CLIA waiver for its point-of-care Sofia 2 Immunoassay analyzer for use with Sofia Influenza A+B Assay Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Quidel receives PMDA approval for its point-of-care SOFIA Influenza A+B Assay

* Quidel receives PMDA approval for its point-of-care Sofia Influenza A+B Assay

BRIEF-Quidel receives FDA clearance for Solana(R) molecular assay for detecting C. difficile infections

* Quidel receives FDA clearance for its new Solana(R) molecular assay for the detection of Clostridium difficile (C. difficile) infections

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up